

- (n) LRWRKRWKRKLWRKRWKRWK (SEQ ID No.41). This peptide is designated MU 35 when referred to herein.
- (o) HRWRKRWKRHRWRKRWKRWK (SEQ ID No.42). This peptide is designated MU 36 when referred to herein.
- (p) RWRKRWKRWRKRWKRWK (SEQ ID No.43). This peptide is designated MU 37 when referred to herein.
- (q) RWRKRGRKRWRKRWKRGRK (SEQ ID No.44). This peptide is designated MU 69 when referred to herein.
- (r) RTRKRWKRTRKRWKRGRK (SEQ ID No.45). This peptide is designated MU 70 when referred to herein.
- (s) RWRKRWKRWRKRWKRWK (SEQ ID No.46). This peptide is designated MU 71 when referred to herein.
- (t) RWRKRWKRWRKRWKRWRKRW (SEQ ID No.47). This peptide is designated MU 84 when referred to herein.

Change(s) applied

to document. Please replace the last paragraph on page ³⁰ 32 with the following rewritten paragraph:

/H.Y.C./
7/13/2011

Figure 4 illustrates data obtained for five peptides identified as GIN 16 (SEQ ID No.2 48), GIN 17 (SEQ ID No.15), GIN 27 (SEQ ID No.16), GIN 28 (SEQ ID No.17), and GIN 30 (SEQ ID No.18). **Figure 4** clearly shows that surprisingly only GIN 16 according to the first aspect showed antiviral activity, whereas GIN 17, GIN 27, GIN 28 and GIN 30 did not.

Change(s) applied

to document,

/H.Y.C./

7/13/2011

Please replace the last paragraph on page ¹¹ 1/2 spanning to page ¹² 1/3 with the following rewritten paragraph:

Preferred peptides according to the first aspect of the invention comprise the amino acid sequence:

- (a) LRTRKGRGRKLRTRKGRGRK (SEQ ID No.2 48). This peptide is designated GIN 16 when referred to herein;
- (b) RTRKGRGRKRTRKGRGRK (SEQ ID No.3). This peptide is designated GIN 35 when referred to herein;
- (c) RTRKGRGRRTRKGRGR (SEQ ID No.4). This peptide is designated GIN 36 when referred to herein;
- (d) LRKRKRLLRKRKRL (SEQ ID No.5). This peptide is designated GIN 37 when referred to herein; and
- (e) LRKRKRLRKLKRKRLRK (SEQ ID No.6). This peptide is designated GIN 38 when referred to herein;
- (f) WRWRKWRWKWRWRKWRWK (SEQ ID No.7). This peptide is designated GIN 33 when referred to herein.
- (g) RRWRKWRWKWRWRKWRWK (SEQ ID No.34). This peptide is designated MU 28 when referred to herein.
- (h) KRWRKWRWKWRWRKWRWK (SEQ ID No.35). This peptide is designated MU 29 when referred to herein.
- (i) LRWRKWRWKWRWRKWRWK (SEQ ID No.36). This peptide is designated MU 30 when referred to herein.
- (j) HRWRKWRWKWRWRKWRWK (SEQ ID No.37). This peptide is designated MU 31 when referred to herein.
- (k) RWRKWRWKWRWRKWRWK (SEQ ID No.38). This peptide is designated MU 32 when referred to herein.
- (l) RRWRKWRWKRRWRKWRWK (SEQ ID No.39). This peptide is designated MU 33 when referred to herein.
- (m) KRWRKWRKKRWRKWRWK (SEQ ID No.40). This peptide is designated MU 34 when referred to herein.